Evercyte GmbH
Evercyte (https://evercyte.com) was founded in 2010 as a spin-off of BOKU University and the Grillari labs. By now it hosts 7 employees in R&D. Evercyte provides relevant human cell lines as model systems for cell based assays, production host for extracellular vesicles, as well as for cellular therapy applications. Evercyte has put a focus on isolating mesenchymal stromal cells from different tissues to set up pre-clinical test systems that represent the human body and allow e.g. toxicity studies, potency assays or drug testings. Moreover, Evercyte’s cells are ideal and innovative cell factories for the production of recombinant complex molecules or extracellular vesicles for pre- and clinical applications.
Prof Regina Grillari
Supervisor of DC8. Prof Grillari is a co-founder and COO/CSO of Evercyte. Prof Grillari has focused on the generation of human relevant and standardizable cell systems for pre-clinical testings and for production of clinical grade extracellular vesicles in the course of her professional career. In 2015 she achieved third place of the Houska Award of the B&C Holding. She has authored more than 70 SCI publications and 5 patents.
Otto Kanzler
Otto Kanzler, CEO and co-founder of Evercyte has more than 30 years’ experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma-industry, specified for strategic and economic issues. Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993). Otto Kanzler is a serial entrepreneur having founded and co-founded several companies, all of which are still active today.
Dr Matthias Wieser
Dr Wieser is head of Cell Line Development of Evercyte, has more than 20 years of experience in immortalizing human primary cells under maintenance of their primary cell characteristics. He has experience in all kinds of cell immortalization techniques, subcloning, gene editing (e.g. using CRISPR/Cas9), 3D co-culturing of cells especially for barrier models. He has co-authored more than 21 SCI papers.
Prof Johannes Grillari
Prof Grillari is the head of the Ludwig Boltzmann Institute for Traumatology,professor of Molecular Biology at BOKU (University of Natural Resources and Life Sciences, Viennaand will act as co-supervisor of DC8. He accomplished his PhD degree in 1999 on senescence of endothelial cells. He has authored more than 180 SCI papers and 14 patents, and was invited as speaker more than 150 times to international meetings. In addition, he is co-founder and scientific advisor of TAmiRNA GmbH, Phoenestra GmbH and Rockfish Bio.